Australia · Delayed Price · Currency is AUD Mesoblast Earnings Call Transcripts
Fiscal Year 2026
-
RYONCIL is driving strong revenue growth and label expansion, while late-stage programs in back pain and heart failure target multi-billion dollar markets. Next-generation MSC innovations and strategic partnerships support a robust pipeline, with financial discipline and manufacturing advances enabling sustainable growth.
-
Ryoncil's launch drove $49M in H1 FY 2026 net revenue, with rapid market adoption and broad payer coverage. Full-year guidance projects $110–$120M in net revenue, while pipeline programs advance toward key regulatory milestones.
Fiscal Year 2025
-
Ryoncil's strong US launch in pediatric acute GVHD is driving significant sales and broad insurance coverage, with plans for adult label expansion and European filings. Pipeline programs target inflammatory and cardiovascular diseases, while financial management and strategic partnerships support growth.
-
Leadership changes and strong commercialization have driven revenue growth, with clinical trials progressing for chronic back pain and heart failure. Regulatory engagement and pipeline expansion into adult and IBD markets are key priorities for 2026.
-
Ryoncil's FDA approval and commercial launch drove a 191% revenue increase, with strong initial uptake and broad insurance coverage. Pivotal trials for label expansion in adult GVHD, IBD, and chronic low back pain are underway, and the company maintains a robust cash position.
-
FDA approval of Ryoncil® for pediatric GvHD drove a strengthened cash position and launch plans, with label extension studies and new indications in progress. Rexlemestrocel-L and REVASCOR® advance in late-stage trials, supported by robust financing and positive market feedback.
-
Received FDA approval for the first allogeneic mesenchymal stromal cell therapy for pediatric GVHD, with imminent US launch and plans to expand into adult and other inflammatory diseases. Strong pipeline in cardiovascular and back pain, robust financials, and strategic global partnerships support growth.
Fiscal Year 2024
-
Ryoncil became the first FDA-approved mesenchymal stromal cell therapy for children with steroid-refractory acute GVHD, with launch planned in the coming weeks. The product's strong safety profile, robust clinical data, and scalable manufacturing set a new benchmark for cell therapies, with further trials and broader indications planned.
-
The AGM highlighted strong financial discipline, progress toward FDA approval and commercialization of Ryoncil, and strategic focus on expanding indications for key products. Shareholders engaged on regulatory, market, and governance topics, with all resolutions put to a poll and results to be released via ASX.
-
Regenerative medicine is at a critical juncture, with a pivotal FDA decision for pediatric GVHD expected January 7th. Robust clinical data support near-term filings in heart failure and ongoing trials in back pain, while commercial launch plans are fully funded and targeted.
-
Significant progress in FDA engagement and clinical pipeline, with Ryoncil BLA resubmitted and commercial launch preparations underway. Cash burn and manufacturing costs reduced, and partnerships established for back pain product in Europe. FDA decisions and reimbursement remain key uncertainties.